摘要
目的:探讨血清CA72-4、CA19-9、CEA联合检测对胃癌的临床价值。方法:对32例中晚期胃癌患者和21例良性胃病患者采用放射免疫法(RIA)分别测定CA72-4、CA19-9和CEA。结果:胃癌组中CA72-4、CA19-9、CEA血清测定值水平、阳性率均明显高于良性胃病组(P < 0.01。其中胃癌组的CA72-4阳性率(59.4%明显高于CA19-9和CEA28.1%。联合检测时胃癌组中各种联合方式阳性率均明显高于良性胃病组,且良性胃病组阳性率不增加,其中胃癌组的联合检测CA72-4+CA19-9、CA72-4+CA19-9+CEA阳性率分别提高到68.8%和71.8%,均明显高于其他联合方式,如CA72-4+CEA(46.8%)、CA19-9+CEA(43.8%。但CA72-4+CA19-9和CA72-4+CA19-9+CEA之间无统计学差异(P >0.05。结论:以CA72-4+CA19-9或CA72-4+CA19-9+CEA联合检测可以提高胃癌的阳性检出率,但不增加良性胃病假阳性率,故对胃癌的早期诊断、疗效监测、预后、复发转移有重要意义。
Objective To explore the clinical value of stomach carcinoma by combining testing the serum levels of CA72-4 CA19-9 Cea. Methods The serum levels of CA72-4 CA19-9 CEA in 32 cases of middle and late stage stomach carcinoma and 21 cases of benign stomach diseases were determined by using RIA method. Results The results showed that the serum levels and the positive rates of CA72-4 CA19-9 CEA were higher in the stomach carcinoma group than those in the benign stomach diseases group with a high statistical significance P< 0.01. The positive rate of CA72-4 in stomach carcinoma group was 59.4% and it was higher than those in CA19-9 37.5% and CEA 28.1%. The positive rate of them in stomach carcinoma group were higher than those in the benign stomach diseases by using combining test P<0.01. The positive rate of benign stomach diseases group was not increased. The results also showed that the positive rates of combining testing CA72-4+CA19.9 and CA72-4+CA19.9+CEA were 68.8% and 71.8% respectively and they were higher than other combining tests such as CA72-4+CEA 46.8% CA19-9+CEA 43.8%. No statistical significance was found between CA72-4+CA19-9 and CA72-4+CA19.9+CEA P >0.05. Conclusion It is concluded that the positive rate may be increased by combining test of CA72-4+CA19-9 or CA72-4+CA19-9+CEA in stomach carcinoma but not in bengin stomach diseases. Thus the combining test might be of high value for the early diagnosis improving the therapeutic effect and prognosis of stomach carcinoma.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2000年第10期776-777,共2页
Chinese Journal of Clinical Oncology